Tamalaki (Bhumyamalaki): Evidence, Liver Research & Safety

TL;DR

Tamalaki (bhumyamalaki) is the Ayurvedic name for several Phyllanthus species: P. fraternus, P. amarus, P. niruri: traditionally used for jaundice and liver disorders. A 2011 Cochrane review found no convincing evidence that Phyllanthus benefits chronic hepatitis B. A 2021 RCT in alcoholic hepatitis found improved antioxidants but no liver-function gains.

(52 words. Sources: Xia et al. 2011, Cochrane; Karri Sowjanya et al. 2021, RCT; AYU pharmacognosy review.)

What it is

Tamalaki, better known as bhumyamalaki, is not a single species. A pharmacognostic review in AYU notes that the drug is attributed to Phyllanthus niruri L., but adds a crucial correction: "*P. niruri* is endemic to West Indies and not found in India," and that several Phyllanthus species: P. amarus, P. fraternus, P. maderaspatensis, P. simplex, P. urinaria: are all traded as "bhumyamalaki" (Pharmacognostic evaluation of Bhumyamalaki, AYU 2011). Bhumyamalaki is an established Ayurvedic drug name for this Phyllanthus group. It is a small annual herb of the family Phyllanthaceae, and the whole plant is used. Its best-studied constituents are the lignans phyllanthin and hypophyllanthin, which the trial authors note have demonstrated hepatoprotective action in earlier studies (Karri Sowjanya et al., 2021).

Traditional use

In the Indian systems of medicine, bhumyamalaki is described as one of the most promising herbal drugs for liver disorders. Literature surveys record its traditional use for jaundice, dysentery, gonorrhea, frequent menstruation, and diabetes, and externally for skin ulcers, sores, and swelling (AYU review, 2011). These are traditional claims, not clinical proof: the trial evidence is assessed separately below.

What modern research says

Chronic hepatitis B — early excitement, later neutral verdicts

The modern research story of Phyllanthus is a cautionary one. An early, small 1988 preliminary study of P. amarus in chronic hepatitis B carriers reported striking HBsAg clearance: a result that drew international attention (Thyagarajan & Blumberg, 1988). A 2001 systematic review of 22 randomized trials (1,947 patients) pooled mostly low-quality studies and found a higher chance of HBsAg clearance with Phyllanthus versus placebo or no intervention (relative risk 5.64, 95% CI 1.85–17.21), with a slightly higher HBeAg clearance rate (41% vs 35%) (Liu et al., 2001, summarized in Asian Pac. J. Trop. Dis. 2017).

But the most rigorous assessment, a 2011 Cochrane review by Xia, Luo, Liu and Gluud, concluded there is "no convincing evidence that phyllanthus, compared with placebo, benefits people with chronic hepatitis B virus infection" (Cochrane Database Syst. Rev. 2011, CD008960). Bottom line: the early signal did not survive better-controlled scrutiny. Phyllanthus is not a substitute for antiviral therapy or hepatology care.

Alcoholic hepatitis — one double-blind RCT

A 2021 block-randomized, double-blind, placebo-controlled trial (Indian Journal of Pharmacology) tested P. niruri extract, 500 mg twice daily for 4 weeks, in 100 patients with mild-to-moderate alcoholic hepatitis (71 analyzed). Liver and renal function parameters did not improve significantly versus placebo. The extract did produce a statistically significant increase in total antioxidant levels (p=0.034) and an appetite-stimulant effect (p=0.03) at 4 weeks, with a good tolerability profile and no treatment discontinuations due to adverse events (Karri Sowjanya et al., 2021). The authors flagged the short 4-week duration as a key limitation.

Kidney stones — little support

A 2020 systematic review and meta-analysis examined P. niruri ("stone breaker") for kidney stones and found little clinical support for marketed stone-inhibiting claims (Dhawan & Olweny, Can. J. Urol. 2020).

What the evidence does not support

Beyond the trials above, there are no controlled human data supporting tamalaki for liver "detox," fatty liver, or viral hepatitis treatment. The hepatoprotective effects of phyllanthin and hypophyllanthin remain preclinical findings.

Dosage

The only trial-based dose in the cited sources is from the alcoholic-hepatitis RCT: **500 mg of P. niruri extract twice daily for 4 weeks**: a research dose, not a personal recommendation (Karri Sowjanya et al., 2021). No pharmacopoeial dose is stated in the cited sources.

Safety & contraindications

FAQs

What is tamalaki (bhumyamalaki)?

The Ayurvedic name for several Phyllanthus species (P. fraternus, P. amarus, P. niruri, and others) traded under one name; P. niruri itself is native to the West Indies, not India (AYU review, 2011).

Does tamalaki cure hepatitis B?

No. An early 1988 preliminary study reported HBsAg clearance, but a 2011 Cochrane review concluded there is no convincing evidence that Phyllanthus benefits chronic hepatitis B versus placebo (Cochrane 2011). It is not a substitute for antiviral therapy.

What did the alcoholic hepatitis trial find?

In 100 patients, P. niruri 500 mg twice daily for 4 weeks did not improve liver or kidney function versus placebo, but did raise total antioxidant levels and appetite, and was well tolerated (Karri Sowjanya et al., 2021).

Does tamalaki help kidney stones?

A 2020 systematic review and meta-analysis found little clinical support for P. niruri products marketed for kidney stones (Dhawan & Olweny, 2020).

What dose of tamalaki was studied?

500 mg of P. niruri extract twice daily for 4 weeks in the alcoholic-hepatitis RCT: a research dose, not a recommendation (Karri Sowjanya et al., 2021).

Is tamalaki safe?

Short-term trial use (4 weeks) was well tolerated with no serious adverse events attributed to it, but trial adverse events have included hyperurinaria and appetite loss. Safety data in pregnancy are lacking, and hepatitis must be managed medically (Karri Sowjanya et al., 2021).

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.